StemRIM Inc. (4599) Other
Market cap
¥19.3B
P/E ratio
StemRim develops regenerative induction pharmaceuticals that activate patients' own stem cells to repair damaged tissues using peptide-based drugs like Ledasemdide.
| 2015/07 | 2016/07 | 2017/07 | 2018/07 | 2019/07 | 2020/07 | 2021/07 | 2022/07 | 2023/07 | 2024/07 | 2025/07 | |
| Return on Assets | - | - | - | - | -31.3 | 11.4 | 6.4 | -4.4 | 1.7 | -5.1 | -23.2 |
| Return on equity (%) | - | - | - | ||||||||
| Employees | 8 | 9 | 18 | 20 | 21 | 34 | 46 | 44 | 44 | 44 | 45 |